Knight Therapeutics (TSE:GUD) Reaches New 12-Month High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high on Monday . The stock traded as high as C$9.98 and last traded at C$9.98, with a volume of 21477 shares traded. The stock had previously closed at C$9.91.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$9.50 price objective on Knight Therapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Knight Therapeutics has a consensus rating of “Buy” and a consensus target price of C$9.50.

Knight Therapeutics Price Performance

The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86. The company has a market capitalization of C$978.84 million, a PE ratio of 166.17, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.21. The stock’s 50-day moving average is C$8.66 and its two-hundred day moving average is C$7.20.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, May 7th. The company reported C$0.13 earnings per share (EPS) for the quarter. The business had revenue of C$147.59 million during the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%. On average, equities analysts predict that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.